CSF1R and neoplasm: PLX3397 (Plexxikon), which functions as a multi-kinase inhibitor targeting CSF-1R-associated kinases and c-kit, could also reduce survival of tumor-infiltrating M2 macrophages and increase infiltration of antitumor CTL in a syngeneic orthotopic murine model of mammary carcinogenesis [191].